Browse the evidence

No significant differences in overall time trial or inclined ride times were observed between intervention groups.

Creatine and carbohydrate loading may not affect overall time trial performance but can enhance specific sprint efforts.

Current guidelines provide limited recommendations for the medical management of patients with obesity-related HFpEF.

Healthcare providers may need to seek additional resources for managing obesity-related HFpEF.

The role of GLP-1 receptor agonists in obesity-related HFpEF remains unclear.

Further research is needed to clarify the role of GLP-1 receptor agonists in managing obesity-related HFpEF.

Low intuitive eating scores were associated with low binge-eating classification rates only if both dichotomous thinking and rigid restraint scores were low.

Practitioners should consider the interplay of multiple eating patterns when assessing binge eating risk.

Higher in vivo adipose cell turnover is positively associated with BMI and VAT/TAT.

Practitioners should consider the role of adipose cell turnover in assessing metabolic health in obese individuals.

Preadipocyte and adipocyte formation is negatively associated with insulin sensitivity.

This finding suggests that higher adipocyte formation may be detrimental to insulin sensitivity, which is crucial for metabolic health.

BAT does not mediate metabolic adaptation to overeating in humans.

BAT is not a factor in how the body adapts to overeating.

Subgroup analyses did not suggest differences in outcomes based on diabetes status or GLP-1 receptor agonist used.

GLP-1 RAs can be considered safe for use in diverse patient populations without increased risk of suicidality.

A single-site measure of muscle shape does not adequately capture the effects of exercise training interventions.

Multiple measurement sites should be used to assess training effects accurately.

Low responders displayed higher plasma leptin levels compared with high responders at baseline.

Understanding leptin levels can help tailor interventions for different responder types.

Nineteen approved and pending Medicaid Section 1115 waivers address nutrition, with eleven submitted or approved since 2021.

Practitioners should be aware of the increasing number of waivers addressing nutrition in Medicaid.

Ingestion of the sports bar impaired subsequent high-intensity time-trial performance.

Care should be taken when using sports bars before high-intensity efforts.

There is no significant difference in muscle hypertrophy between segments in the placebo group.

Placebo may not be effective for muscle hypertrophy in resistance training contexts.

Magnitude of residual variation in weight was associated with all-cause mortality (relative risk, 1.25 for 1 U of additional variation; 95% CI, 1.06-1.47).

Practitioners should consider the impact of weight fluctuations on overall mortality risk.

Magnitude of residual variation in weight was associated with ischemic heart disease mortality (relative risk, 2.49; 95% CI, 1.41-4.38).

Weight management strategies should be carefully considered to reduce heart disease risk.

Weight loss interventions, if deemed to be necessary, should be considered carefully.

Practitioners should approach weight loss interventions with caution, considering potential risks.

Restraint, disinhibition, and physical activity level did not predict weight change.

Practitioners should note that traditional factors like restraint and activity may not be reliable indicators of weight change in this population.

Fat intake does not promote fat oxidation, leading to fat deposition.

Reducing fat intake may help in managing fat deposition and obesity.

Several compounds targeting the central nervous system and/or periphery are in development for obesity treatment.

Practitioners should stay informed about new drug developments targeting obesity.

Long-term safety monitoring of new obesity drugs is necessary due to potential serious adverse events.

Practitioners should prioritize safety monitoring for new obesity treatments.

The estimated health care cost offsets from clinical benefits of GLP-1RAs are projected to be $18.2 billion over 10 years.

Practitioners should consider the potential health care savings from clinical benefits of GLP-1RAs.

No significant effect of frequency was found for muscle hypertrophy.

Older adults may not experience additional muscle growth benefits from increasing resistance training frequency beyond two sessions per week.

GLP-1-RAs are known to delay gastric emptying.

Understanding the effect of GLP-1-RAs on gastric emptying is crucial for perioperative management.

No significant gender by time interaction was observed during the second 8-week phase of the resistance training program.

Results suggest that initial gender differences in training load may not persist over longer training periods.